Lamotrigine in childhood epilepsies (Q30470260)

21 June 2017

1 reference

title

Lamotrigine in childhood epilepsies (English)

1 reference

21 June 2017

1 reference

F E Dreifuss

1

1 reference

21 June 2017

publication date

1 March 1997

1 reference

Seminars in pediatric neurology

21 June 2017

published in

1 reference

21 June 2017

volume

4

1 reference

21 June 2017

issue

1

1 reference

21 June 2017

page(s)

19-23

1 reference

The development of antiepileptic drugs for children. Report from the NIH workshop, Bethesda, Maryland, February 17-18, 1994

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Sodium valproate acutely inhibits lamotrigine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Controlled trial of lamotrigine (Lamictal) for refractory partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Overview of the Clinical Efficacy of Lamotrigine

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Lamotrigine as an add-on drug in typical absence seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Lamotrigine: clinical experience in 93 patients with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Lamotrigine in treatment of 120 children with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Lamotrigine for the treatment of epilepsy in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Lamotrigine in primary generalised epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Lamotrigine in resistant childhood epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Vigabatrin and lamotrigine in refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Epilepsy with myoclonic absences

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Management issues in severe childhood epilepsies

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Lamotrigine in infantile spasms

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

Lamotrigine in Rett syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2897%2980005-8

7 January 2021

10.1016/S1071-9091(97)80005-8

Identifiers

DOI

1 reference

21 June 2017

1 reference